Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

Press/Media: Press / Media

PeriodNov 13 2016 → Nov 18 2016

Media coverage

43

Media coverage

  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date11/18/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletPipelineReview
    CountrySpain
    Date11/14/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletTMC Net
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletNasdaq
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletIndia Pharma News
    CountryIndia
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletYahoo! Finance UK and Ireland
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletPresentation Master
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletPharmacy Choice
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletStock Nod
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletBusiness Wire
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletChannel 8 Eyewitness News
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletCW Richmond WUPV
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outlet35 WSEE
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletFox 19
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWLBT
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWOWK
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWBOC TV 16
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWALB 10
    CountryGeorgia
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWLTZ 38
    CountryGeorgia
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKTRE
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKuam News 8
    CountryGuam
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKPTV.com
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKCBD
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKTVN
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKait 8
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletNewsChannel 10
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKSLA
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKAUZ
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWTRF
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKOTV
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKFVS12
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWSFA
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWMBF
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletFox 8 WVUE New Orleans
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKUSI.com
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWFLX Fox 29
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKSWO
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKHQ Right Now
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWVNS
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletHawaii News Now
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWLOX
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletWTVM
    CountryGeorgia
    Date11/13/16
    PersonsEric J Lawitz
  • TitleMerck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
    Media name/outletKXXV-TV
    CountryUnited States
    Date11/13/16
    PersonsEric J Lawitz